Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $25.15 in the prior trading day, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $25.56, up 1.63%. In other words, the price has increased by $1.63 from its previous closing price. On the day, 0.41 million shares were traded. PTGX stock price reached its highest trading level at $25.825 during the session, while it also had its lowest trading level at $25.13.
Ratios:
Our goal is to gain a better understanding of PTGX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.71 and its Current Ratio is at 16.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on October 30, 2023, initiated with a Overweight rating and assigned the stock a target price of $32.
On August 25, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $21.JMP Securities initiated its Mkt Outperform rating on August 25, 2022, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 18 ’24 when Ali Asif sold 1,234 shares for $25.11 per share. The transaction valued at 30,986 led to the insider holds 37,163 shares of the business.
PATEL DINESH V PH D sold 25,000 shares of PTGX for $707,750 on Apr 01 ’24. The President and CEO now owns 549,590 shares after completing the transaction at $28.31 per share. On Mar 01 ’24, another insider, PATEL DINESH V PH D, who serves as the President and CEO of the company, sold 30,000 shares for $31.62 each. As a result, the insider received 948,600 and left with 574,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 1489508992 and an Enterprise Value of 1149032960. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.82 while its Price-to-Book (P/B) ratio in mrq is 4.38. Its current Enterprise Value per Revenue stands at 19.151 whereas that against EBITDA is -12.399.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.08, which has changed by 0.07711756 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $33.34, while it has fallen to a 52-week low of $13.72. The 50-Day Moving Average of the stock is -9.67%, while the 200-Day Moving Average is calculated to be 17.17%.
Shares Statistics:
The stock has traded on average 662.70K shares per day over the past 3-months and 427920 shares per day over the last 10 days, according to various share statistics. A total of 57.71M shares are outstanding, with a floating share count of 54.80M. Insiders hold about 5.96% of the company’s shares, while institutions hold 95.60% stake in the company. Shares short for PTGX as of 1713139200 were 3522717 with a Short Ratio of 5.32, compared to 1710460800 on 3418311. Therefore, it implies a Short% of Shares Outstanding of 3522717 and a Short% of Float of 6.12.
Earnings Estimates
The firm’s stock currently is rated by 5.0 analysts. On average, analysts expect EPS of $1.19 for the current quarter, with a high estimate of $3.95 and a low estimate of -$0.62, while EPS last year was -$0.67. The consensus estimate for the next quarter is $0.34, with high estimates of $4.19 and low estimates of -$0.66.
Analysts are recommending an EPS of between $2.49 and -$2.71 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is -$0.81, with 5.0 analysts recommending between $2.14 and -$3.27.
